SCHEMBL20166060

SCHEMBL20166060

CCOC(=O)COc1nccc(Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 2/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HSD17B10 Q99714 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HPGD P15428 2/20 0.44
CASP1 P29466 1/20 0.44
NLRP3 Q96P20 2/20 0.43
GAA P10253 2/20 0.43
POLB P06746 2/20 0.40
TBXAS1 P24557 1/20 0.40
RAB9A P51151 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12885398 0.83 TSHR (0.51) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL10175016 0.81 HSD17B10 (0.44) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL29852312 0.79 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL315714 0.79 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL7029492 0.78 POLB (0.42) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL20165978 0.77 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL14444172 0.76 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL31715441 0.76 KDM4E (0.56) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6085711 0.74 ALDH1A1 (0.42) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL11838953 0.74 LMNA (0.52) KDM4EALDH1A1KMT2AHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190345138-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 US disclosed
US-20190345138-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 US disclosed
EP-3541813-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-09-25 EP disclosed
WO-2018092089-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-24 WO disclosed
WO-2018092089-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345138-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 KDM4E 635/4885ALDH1A1 1319/4885SMN1; SMN2 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.